NCT02578836

Brief Summary

This study assesses weight loss from the Endoscopic Vertical Gastroplasty or Fogel Gastroplasty (FG). The purpose of the study is to:

  • Document that weight loss occurs (12 months)
  • Determine if it alters general wellbeing (emotionally and physically)

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Aug 2017

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 15, 2015

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 19, 2015

Completed
1.8 years until next milestone

Study Start

First participant enrolled

August 1, 2017

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2018

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2018

Completed
Last Updated

August 31, 2017

Status Verified

May 1, 2017

Enrollment Period

7 months

First QC Date

October 15, 2015

Last Update Submit

August 29, 2017

Conditions

Keywords

Weight LossOverweightEndoscopic treatment for obesity

Outcome Measures

Primary Outcomes (1)

  • Weight Loss

    12 months

Secondary Outcomes (4)

  • Emotional Wellbeing

    12 months

  • Change in blood pressure

    baseline to 12 months

  • Change in cholesterol level

    baseline to 12 months

  • Change in glucose levels

    baseline to 12 months

Study Arms (1)

Fogel Gastroplasty

EXPERIMENTAL

The subject will be placed under general anesthesia. The procedure will last approximately 1-2 hours. CO2 will be used rather than air for the insufflation that is required during the procedure to minimize abdominal distention. The physician will place an interrupted suture pattern in a manner which partitions the greater curvature of the stomach from the Angle of His to the level of the incisura, creating a tube-like passage for gastric volume reduction. Afterwards, the remaining gastric volume will be reduced using a circumferential running stitch.The device that will be used to place the stitches is the OverStitch system FDA approved for tissue apposition

Procedure: Fogel Gastroplasty

Interventions

The subject will be placed under general anesthesia. The procedure will last approximately 1-2 hours. CO2 will be used rather than air for the insufflation that is required during the procedure to minimize abdominal distention. The physician will place an interrupted suture pattern in a manner which partitions the greater curvature of the stomach from the Angle of His to the level of the incisura, creating a tube-like passage for gastric volume reduction. Afterwards, the remaining gastric volume will be reduced using a circumferential running stitch.The device that will be used to place the stitches is the OverStitch system FDA approved for tissue apposition

Also known as: Endoscopic Vertical Gastroplasty
Fogel Gastroplasty

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Subject is ≥ 18 yrs. of age and ≤ 60 yrs. of age
  • Subject has a BMI between 28 and 34.9
  • Subject is willing to complete all follow-up visits after procedure ( 3, 6 and 12 months)

You may not qualify if:

  • Patients that are not willing to participate in the study
  • Patients with history of Gastrointestinal tumors, Gastric Cancer, previous bariatric, gastric or esophageal surgery; intestinal obstruction; portal gastropathy, esophageal or gastric varices, or gastroparesis,
  • Subject has significant esophageal disease including Zenker's diverticulum, grade 3-4 reflux esophagitis, stricture, Barrett's esophagus, esophageal cancer, esophageal diverticulum, dysphagia, achalasia, or symptoms of dysmotility or Hiatal Hernia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Miami Clinical Research Building

Miami, Florida, 33136, United States

Location

MeSH Terms

Conditions

ObesityOverweightWeight Loss

Condition Hierarchy (Ancestors)

OvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsBody Weight Changes

Study Officials

  • Roberto Fogel, MD

    University of Miami

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate professor

Study Record Dates

First Submitted

October 15, 2015

First Posted

October 19, 2015

Study Start

August 1, 2017

Primary Completion

March 1, 2018

Study Completion

November 1, 2018

Last Updated

August 31, 2017

Record last verified: 2017-05

Locations